NicOx S.A. - Product Pipeline Review - 2015

Published: Jun, 2015 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

NicOx S.A. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'NicOx S.A. - Product Pipeline Review - 2015', provides an overview of the NicOx S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NicOx S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of NicOx S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NicOx S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the NicOx S.A.'s pipeline products

Reasons to buy

- Evaluate NicOx S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NicOx S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NicOx S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NicOx S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NicOx S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of NicOx S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
NicOx S.A. Snapshot 6
NicOx S.A. Overview 6
Key Information 6
Key Facts 6
NicOx S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
NicOx S.A. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
NicOx S.A. - Pipeline Products Glance 14
NicOx S.A. - Late Stage Pipeline Products 14
Filing rejected/Withdrawn Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
NicOx S.A. - Clinical Stage Pipeline Products 16
Phase I Products/Combination Treatment Modalities 16
NicOx S.A. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
NicOx S.A. - Unknown Stage Pipeline Products 19
Unknown Products/Combination Treatment Modalities 19
NicOx S.A. - Drug Profiles 20
naproxcinod 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
cetirizine hydrochloride 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
fluticasone propionate 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
cerdulatinib 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NCX-1021 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
NCX-250 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NCX-422 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NCX-429 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NCX-434 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NCX-466 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NCX-470 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NCX-667 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Activate sGC for Ophthalmology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules for Cardiovascular Disease 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NicOx S.A. - Pipeline Analysis 35
NicOx S.A. - Pipeline Products by Target 35
NicOx S.A. - Pipeline Products by Route of Administration 37
NicOx S.A. - Pipeline Products by Molecule Type 38
NicOx S.A. - Pipeline Products by Mechanism of Action 39
NicOx S.A. - Recent Pipeline Updates 40
NicOx S.A. - Dormant Projects 44
NicOx S.A. - Discontinued Pipeline Products 45
Discontinued Pipeline Product Profiles 45
NCX-1000 45
naproxcinod 45
NCX-1236 45
NCX-226 45
NCX-285 45
NCX-6560 46
NicOx S.A. - Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables

NicOx S.A., Key Information 6
NicOx S.A., Key Facts 6
NicOx S.A. - Pipeline by Indication, 2015 8
NicOx S.A. - Pipeline by Stage of Development, 2015 10
NicOx S.A. - Monotherapy Products in Pipeline, 2015 11
NicOx S.A. - Partnered Products in Pipeline, 2015 12
NicOx S.A. - Partnered Products/ Combination Treatment Modalities, 2015 13
NicOx S.A. - Filing rejected/Withdrawn, 2015 14
NicOx S.A. - Phase III, 2015 15
NicOx S.A. - Phase I, 2015 16
NicOx S.A. - Preclinical, 2015 17
NicOx S.A. - Discovery, 2015 18
NicOx S.A. - Unknown, 2015 19
NicOx S.A. - Pipeline by Target, 2015 36
NicOx S.A. - Pipeline by Route of Administration, 2015 37
NicOx S.A. - Pipeline by Molecule Type, 2015 38
NicOx S.A. - Pipeline Products by Mechanism of Action, 2015 39
NicOx S.A. - Recent Pipeline Updates, 2015 40
NicOx S.A. - Dormant Developmental Projects,2015 44
NicOx S.A. - Discontinued Pipeline Products, 2015 45
NicOx S.A., Subsidiaries 47